Clinical trial
Treat-and-extend Using Aflibercept for Type 3 Neovascularization
NCT04655482 is registered in ClinicalTrials.gov with Kim's Eye Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Treat-and-extend Using Aflibercept for Type 3 Neovascularization
- Lead sponsor
- Kim's Eye Hospital
- Phase
- Phase 4
- Overall status
- Unknown status
- Start date
- February 1, 2021
- Completion date
- August 20, 2024
- Enrollment
- 30 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
retinal angiomatous proliferation